

## POSTER PRESENTATION

## Open Access

# NO-donors induce cross talk between cGMP and cAMP in signalling to human atrial L-type $\text{Ca}^{2+}$ current

Nadiia Rozmaritsa\*, Torsten Christ, Erich Wettwer, Ursula Ravens

From 5th International Conference on cGMP: Generators, Effectors and Therapeutic Implications  
Halle, Germany. 24-26 June 2011

## Background

Cardiac NO-activated pathways are discussed to involve cross-talk between cGMP and cAMP signalling [1,2]. Here we have investigated the signalling pathways relating to NO-donor S-nitroso-N-acetylpenicillamine (SNAP) modulation of L-type  $\text{Ca}^{2+}$  current ( $I_{\text{Ca,L}}$ ) in human right atrial cardiomyocytes.


## Material and methods

Experiments were performed on human biopsy tissue from 62 patients in sinus rhythm.  $I_{\text{Ca,L}}$  was measured with whole-cell voltage-clamp technique.

## Results

Application of SNAP (100  $\mu\text{M}$ ) increased basal  $I_{\text{Ca,L}}$  from  $5.93 \pm 0.23$  pA/pF to  $9.10 \pm 0.45$  pA/pF ( $p < 0.001$ ,  $n/N = 117/62$ ). The effect was abolished by inhibition of soluble guanylate cyclase (sGC) with ODQ (30  $\mu\text{M}$ ), suggesting involvement of cGMP. Stimulator of sGC (BAY 41-2272, 10 nM–10  $\mu\text{M}$ ) also increased  $I_{\text{Ca,L}}$  and this effect was potentiated in the presence of SNAP. Direct activation of protein kinase G (PKG) with 8-Br-cGMP (100  $\mu\text{M}$ , intracellular application) increased basal  $I_{\text{Ca,L}}$ . However, not only cGMP but also cAMP was involved, because, the effect of SNAP on  $I_{\text{Ca,L}}$  was prevented with the protein kinase A blocker (Rp-8-Br-cAMP 1 mM, intracellular). Thus, cGMP may activate  $I_{\text{Ca,L}}$  via direct activation of PKG and indirect activation of PKA at the same time. It is known, that cAMP-mediated activation of PKA is regulated by cGMP via modulation of phosphodiesterases (PDEs). The selective PDE2 inhibitor EHNA (10  $\mu\text{M}$ ) did

not affect basal or SNAP-stimulated  $I_{\text{Ca,L}}$ , therefore PDE2 does not regulate basal cAMP level. In contrast, PDE3 inhibition with cilostamide (1  $\mu\text{M}$ ) increased basal  $I_{\text{Ca,L}}$ , suggesting that PDE3 is involved in basal cAMP level regulation. Interestingly, the cilostamide-induced increase in  $I_{\text{Ca,L}}$  is blunted upon addition of SNAP, most probably via activation of PDE2 by SNAP-mediated cGMP increase (Figure 1). Similarly, SNAP blunted enhancement of  $I_{\text{Ca,L}}$  by PKA activation with isoprenaline (1  $\mu\text{M}$ ;  $18.07 \pm 1.12$  pA/pF vs  $23.06 \pm 1.36$  pA/pF,  $p < 0.001$ ,  $n/N = 21-39/18$ ), however, this effect was prevented by PDE2 inhibition with EHNA.



**Figure 1** Effect of SNAP (100  $\mu\text{M}$ ), PDE2 inhibitor (EHNA, 10  $\mu\text{M}$ ) and PDE3 inhibitor (Cilostamide, 1  $\mu\text{M}$ ) on  $I_{\text{Ca,L}}$ . SNAP effect in the presence of cilostamide.

\* Correspondence: [nadiia.rozmaritsa@tu-dresden.de](mailto:nadiia.rozmaritsa@tu-dresden.de)  
Department of Pharmacology and Toxicology, Dresden University of  
Technology, Dresden, 01307, Germany

## Conclusion

We conclude that in human atrial cardiomyocytes NO-donors stimulate production of cGMP with further cross-talk to cAMP via PDE2 and PDE3.

Published: 1 August 2011

## References

1. Castro LR, Schittl J, Fischmeister R: **Feedback control through cGMP-dependent protein kinase contributes to differential regulation and compartmentation of cGMP in rat cardiac myocytes.** *Circ Res* 2010, **107**:1232-1402.
2. Stangherlin A, Gesellchen F, Zoccarato A, Terrin A, Fields LA, Berrera M, Surdo NC, Craig MA, Smith G, Hamilton G, Zaccolo M: **cGMP signals modulate cAMP levels in a compartment-specific manner to regulate catecholamine-dependent signaling in cardiac myocytes.** *Circ Res* 2011, **108**:929-939.

doi:10.1186/1471-2210-11-S1-P55

**Cite this article as:** Rozmaritsa et al.: NO-donors induce cross talk between cGMP and cAMP in signalling to human atrial L-type Ca<sup>2+</sup> current. *BMC Pharmacology* 2011 **11**(Suppl 1):P55.

**Submit your next manuscript to BioMed Central  
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

